News

Boosting regenerative medicine
Enlarge image

FundingUKGermanySpainNetherlands

Boosting regenerative medicine

30.05.2012 - Regenerative medicine centres foster their translational approach. An international initiative formed in Germany, a new centre is opened in Scotland.

Edinburgh/Enschede/Seville/Berlin/Toronto – The Scottish Centre for Regenerative Medicine (SCRM) officially started operations on May 28. The SCRM will conduct cutting-edge stem cell research to find new therapies for Multiple Sclerosis, Parkinson’s disease, motor neuron disease and heart and liver disease. Up to 250 scientists will work at the centre, which is funded by the University of Edinburgh, the Medical Research Council, Scottish Enterprise and the British Heart Foundation with up to £54m. The SCRM will put an special emphasis on translational efforts, turning laboratory discoveries faster into treatments. An additional newly founded £24m bioincubator, named „Nine, Edinburgh Bioquarter“ offers lab and office space to start-up ventures and established biotech companies.

Just days before, the Regenerative Medicine Coalition constituted itself in Germany’s capital city Berlin. Six translational medicine centres from Europe and North America joined forces to push stem cell based medicine forward. The Berlin-Brandenburg Centre for Regenerative Therapies (BRCT, Berlin, Germany), the Centre for Commercialisation of Regenerative Medicine (Toronto, Canada), the MIRA Institute for Biomedical Technology and Technical Medicine (Enschede, The Netherlands), the Andalusian Molecular Biology and Regenerative Medicine Centre (Seville, Spain), the McGowan Institute of Regenerative Medicine (Pittsburgh, USA) and the Institute for Regenerative Medicine (Winston Salem, USA) are among the founding members. „We plan to jointly tackle projects in order to accelerate the development of therapies”, announced Frank Lauter from BRCT.

http://www.european-biotechnology-news.com/news/news/2012-02/boosting-regenerative-medicine.html

LicensingSwitzerland

30.08.2016 Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ARGEN-X (B)14.20 EUR5.19%
  • MAGFORCE (D)4.71 EUR4.43%
  • DIAMYD MEDICAL -B- (S)7.20 SEK4.35%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-6.82%
  • PHOTOCURE (N)41.00 NOK-6.61%
  • SAREUM HOLDINGS (UK)0.74 GBP-5.13%

TOP

  • NORDIC NANOVECTOR (N)34.50 NOK40.8%
  • KARO BIO (S)43.10 SEK30.6%
  • MOLMED (I)0.42 EUR27.3%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-28.1%
  • GW PHARMACEUTICALS (UK)514.61 GBP-13.6%
  • WILEX (D)1.46 EUR-13.6%

TOP

  • NICOX (F)10.29 EUR430.4%
  • SAREUM HOLDINGS (UK)0.74 GBP236.4%
  • GENMAB (DK)1085.00 DKK81.6%

FLOP

  • BB BIOTECH (D)44.30 EUR-82.9%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)92.00 GBP-73.1%

No liability assumed, Date: 30.08.2016